Holocene

BioStem Technologies Reports Third Quarter 2022 Operating and Financial Results

Retrieved on: 
Tuesday, November 15, 2022

POMPANO BEACH, FLORIDA., Nov. 15, 2022 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today reported financial results for the quarter ended September 30, 2022.

Key Points: 
  • Company to Host a Conference Call and Webcast on November 15, 2022, at 4:30 pm EDT
    POMPANO BEACH, FLORIDA., Nov. 15, 2022 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today reported financial results for the quarter ended September 30, 2022.
  • Jason Matuszewski, Chief Executive Officer of BioStem Technologies Inc. said, Over the third quarter, we have continued to build on the strengths of our growth strategy.
  • Net revenue of $1.145 million for quarter ended September 30, 2022, down 13%, compared to net revenue of $1.313 million for the quarter ended September 30, 2021.
  • Quarter and Year-to Date ending September 30, 2022 Results:
    The following table represents net revenue, gross margin, operating expenses, and other income (loss) for the three and Nine-months ended September 30, 2022, and September 30, 2021, respectively:
    Three months ended September 30,
    Nine months ended September 30,

Onconova Therapeutics Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer, Reports Third Quarter 2022 Financial Results, and Provides a Business Update

Retrieved on: 
Monday, November 14, 2022

NEWTOWN, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced plans for a Phase 1/2a trial of narazaciclib combined with letrozole in recurrent metastatic low-grade endometrioid endometrial cancer (LGEEC). In addition, the Company reported its third quarter 2022 financial results and provided a business update.

Key Points: 
  • In addition, the Company reported its third quarter 2022 financial results and provided a business update.
  • Moreover, none are currently FDA approved for endometrial cancer, creating an urgent need for improved treatment options for LGEEC patients.
  • Endometrial cancer (EC) arises in the uterine lining and is the most common cancer of the female reproductive organs.
  • Endometrioid endometrial cancer is the most common subtype of EC, accounting for approximately 75% of cases.

GENESCO STRENGTHENS BOARD WITH APPOINTMENT OF TWO NEW INDEPENDENT DIRECTORS MATT BILUNAS AND CAROLYN BOJANOWSKI

Retrieved on: 
Tuesday, November 22, 2022

Greg Sandfort, Genesco's Lead Independent Director, said, "We welcome Matt and Carolyn to the Genesco Board.

Key Points: 
  • Greg Sandfort, Genesco's Lead Independent Director, said, "We welcome Matt and Carolyn to the Genesco Board.
  • We are committed to our ongoing board refreshment, including maintaining a highly engaged, independent board, while ensuring we have the right mix of skills and expertise.
  • On behalf of the Board, I'd like to thank Matt and Kevin for their exemplary service, dedication and commitment to Genesco and all of our stakeholders."
  • Mimi Vaughn, Board Chair, President and Chief Executive Officer of Genesco, added, "I am delighted to welcome seasoned retail executives Matt Bilunas and Carolyn Bojanowski to our Board.

Prenetics Announces Record Third Quarter 2022 Financial Results and Raises Full Year 2022 Revenue and EBITDA Guidance

Retrieved on: 
Thursday, November 10, 2022

Prenetics provides guidance based on current market conditions and expectations for revenue and adjusted EBITDA, which is a non-IFRS financial measure.

Key Points: 
  • Prenetics provides guidance based on current market conditions and expectations for revenue and adjusted EBITDA, which is a non-IFRS financial measure.
  • For full year 2022, Prenetics raises revenue guidance to the range of US$270 million to US$280 million and raises full year adjusted EBITDA guidance to the range of US$47 million to US$53 million.
  • Unaudited Financial Information and Non-IFRS Financial Measures has been provided in the financial statements tables included at the end of this press release.
  • An explanation of these measures is also included below under the heading "Unaudited Financial Information and Non-IFRS Financial Measures."

AVITA Medical Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 10, 2022

VALENCIA, Calif. and MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the Company), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today reported financial results for the third quarter ended September 30, 2022.

Key Points: 
  • VALENCIA, Calif. and MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the Company), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today reported financial results for the third quarter ended September 30, 2022.
  • The Company will host a conference call to discuss the third quarter financial results after NASDAQ market close on Thursday, November 10, 2022, at 1:30 p.m. Pacific Time (being Friday, November 11, 2022, at 8:30 a.m. Australian Eastern Daylight Time).
  • AVITA Medical has provided in this release certain financial information that has not been prepared in accordance with GAAP.
  • However, the non-GAAP financial measures that AVITA Medical uses may differ from measures that other companies may use.

KULR Technology Group Reports Record Third Quarter 2022 Financial Results

Retrieved on: 
Wednesday, November 9, 2022

SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- KULR Technology Group, Inc. (NYSE American: KULR) (the "Company" or "KULR"), a leading energy management platform company accelerating the global transition to a sustainable electrification economy, today reported results for the third quarter ended September 30, 2022.

Key Points: 
  • SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- KULR Technology Group, Inc. (NYSE American: KULR) (the "Company" or "KULR"), a leading energy management platform company accelerating the global transition to a sustainable electrification economy, today reported results for the third quarter ended September 30, 2022.
  • Gross Margins: Gross margin was 33% in the quarter ended September 30, 2022, compared to 74% in the same period last year.
  • The third quarter was an inflection point for KULR as we achieved record revenue results and began transitioning to the next chapter of our growth story, said KULR CEO Michael Mo.
  • About KULR Technology Group Inc.
    KULR Technology Group Inc. (NYSE American: KULR) is a leading energy management platform offering proven solutions that play a critical role in accelerating the electrification of the circular economy.

Nuwellis, Inc. Reports Third Quarter 2022 Financial Results

Retrieved on: 
Tuesday, November 8, 2022

MINNEAPOLIS, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the third quarter ended September 30, 2022.

Key Points: 
  • MINNEAPOLIS, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the third quarter ended September 30, 2022.
  • Total revenue for the third quarter of 2022 was $2.1 million, an increase of 11% compared to the third quarter of 2021.
  • Gross margin was 61.0% for the third quarter of 2022 compared to 60.4% in the prior-year period.
  • Selling, general and administrative expenses for the third quarter of 2022 were $4.3 million, compared to $4.6 million in the prior-year period.

InspireMD Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 8, 2022

TEL AVIV, Israel, Nov. 08, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for treatment of carotid artery disease (CAD) and prevention of stroke today announced financial and operating results for the third quarter ended September 30, 2022.

Key Points: 
  • Financial Results for the Third Quarter ended September 30, 2022
    For the third quarter of 2022, total revenue increased 33.6%, to $1,431,000, from $1,071,000 during the third quarter of 2021.
  • Gross profit for the third quarter of 2022 increased by $274,000, or 297.8%, to $366,000, compared to a gross profit of $92,000 for the third quarter of 2021.
  • Total operating expenses for the third quarter of 2022, were $4,976,000, an increase of $853,000, or 20.7% compared to $4,123,000 for the third quarter of 2021.
  • Management will host a conference call at 8:30AM ET today, November 8th, to review financial results and provide an update on corporate developments.

Minerva Surgical Announces Change of Date for Third Quarter 2022 Earnings Release and Conference Call

Retrieved on: 
Monday, November 7, 2022

SANTA CLARA, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a womans health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it has changed the date of its previously announced earnings conference call.

Key Points: 
  • SANTA CLARA, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a womans health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it has changed the date of its previously announced earnings conference call.
  • It will now report its third quarter 2022 financial results on Monday, November 14, 2022.
  • In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
  • Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women.

Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, November 8, 2022

Third Quarter 2022 and Recent Operational Highlights:

Key Points: 
  • Third Quarter 2022 and Recent Operational Highlights:
    Preclinical Data for Four New Pipeline Programs at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.
  • Preclinical data from four new pipeline programs will be presented at the SITC 37th Annual Meeting on November 10-11, 2022.
  • Adicet is hosting an R&D webcast event on Thursday, November 10, 2022, at 9:00 a.m.
  • Based on data collected on ADI-001, Adicet expects to establish the recommended Phase 2 dose for ADI-001 in the second half of 2022.